University of Cincinnati AIDS Clinical Trials Unit- UC ACTU
辛辛那提大学艾滋病临床试验中心 - UC ACTU
基本信息
- 批准号:8197782
- 负责人:
- 金额:$ 166.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-01-19 至 2013-11-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS clinical trial groupAcquired Immunodeficiency SyndromeAnti-Retroviral AgentsCardiovascular DiseasesChildClinicalClinical ManagementClinical ResearchClinical TrialsClinical Trials NetworkClinical Trials UnitCommunity OutreachComorbidityData QualityDiseaseDyslipidemiasEnrollmentFundingGoalsGood Clinical PracticeHIVHIV InfectionsHepatitisLeadershipLifeNational Institute of Allergy and Infectious DiseasePerformancePersonsPharmaceutical PreparationsPopulationPrincipal InvestigatorResearch PersonnelResourcesSiteSpecimen HandlingStagingToxic effectTraining and EducationTranslational ResearchUnited StatesUniversitiesVaccine ResearchWeightWorkclinical research sitecostdrug developmentexperiencehigh standardnovel therapeutic interventionpreventquality assurancetransmission processtreatment strategyvaccine developmentworking group
项目摘要
DESCRIPTION (provided by applicant):
Each year there are ~40-60,000 new HIV infections in the United States with ~1.1 million persons living with HIV. There are many important unresolved management issues including the optimal antiretroviral treatment strategy at different stages of HIV disease, treatment of co-morbidities and minimizing of drug-associated toxicities. The University of Cincinnati AIDS Clinical Trials Unit (UC ACTU) has been an NIAID-funded AIDS Clinical Trials Group (ACTG) site since 1987. In this application the UC ACTU proposes to establish a Clinical Trials Unit (CTU) and Clinical Research Site (CRS) affiliated with the ACTG leadership application. This highly-experienced CTU, which was 5th in overall accrual and 3rd in cost per weighted accrual among 34 main ACTG units over the last 3 years, will continue to build upon its exemplary performance, scientific and resource committee contributions to provide leadership within a world-class clinical trials network (ACTG) with the scientific goals of developing new therapeutic approaches (translational research/drug development); optimizing clinical management including toxicities and co-morbidities; preventing maternal-child transmission; and vaccine research and development. To accomplish the goals of the ACTG the UC ACTU will: 1) Establish an administrative core CTU including a principal investigator, clinical trials manager, regulatory manager, data/Quality assurance manager, staff training and education, specimen processing, community outreach and administrative support to provide oversight, coordination and scientific expertise required to operate a high-performing CTU that will interface with the overall agenda/work of the ACTG; 2) Contribute to the ACTG scientific agenda by enrolling subjects in studies, generating new proposals participating in study teams and committees to advance the work of the group; 3) Establish a CRS that can maintain 20 subjects on study per month with the capability of following 100 subjects annually focusing enrollment on under-represented populations and utilizing the highest standards of good clinical practice for clinical research units. Thus, the UC ACTU, led by Dr. Judith Feinberg, an experienced HIV clinical researcher with support from leading experts in the fields of hepatitis (Dr. Ken Sherman) and HIV associated dyslipidemia/ cardiovascular disease (Dr. Carl Fichtenbaum), will contribute to the improvement in the lives of those with HIV infection through its excellence in clinical research.
ADMINISTRATIVE COMPONENT:
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carl J Fichtenbaum其他文献
Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial
他汀类药物对全球 HIV 感染者重大非心血管疾病事件发生率的影响:一项随机对照试验
- DOI:
10.1016/s2352-3018(24)00345-x - 发表时间:
2025-04-01 - 期刊:
- 影响因子:13.000
- 作者:
Marissa R Diggs;Triin Umbleja;Sara McCallum;Markella V Zanni;Sarah M Chu;Kathleen V Fitch;Gerald S Bloomfield;Judith S Currier;Esteban Martinez;Philip E Castle;Aya Awwad;Mamta K Jain;Roger Bedimo;Bronwyn Hendricks;Jose Narrea;Vincente Estrada;Jorge Pinto;Judith A Aberg;Carlos D Malvestutto;Carl J Fichtenbaum;Steven K Grinspoon - 通讯作者:
Steven K Grinspoon
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis
REPRIEVE 试验中抗逆转录病毒药物对主要不良心血管事件的影响:一项纵向队列分析
- DOI:
10.1016/s2352-3018(25)00043-8 - 发表时间:
2025-07-01 - 期刊:
- 影响因子:13.000
- 作者:
Carl J Fichtenbaum;Carlos D Malvestutto;Maya G Watanabe;Emma Davies Smith;Heather J Ribaudo;Sara McCallum;Kathleen V Fitch;Judith S Currier;Marissa R Diggs;Sarah M Chu;Judith A Aberg;Michael T Lu;Javier Valencia;Cristina Gómez-Ayerbe;Indira Brar;Jose Valdez Madruga;Gerald S Bloomfield;Pamela S Douglas;Markella V Zanni;Steven K Grinspoon;Wadzanai P. Samaneka - 通讯作者:
Wadzanai P. Samaneka
Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE
在一项全球心血管疾病预防试验中,HIV 感染者的合并队列方程和 D:A:D 风险评分的性能:一项利用 REPRIEVE 数据的队列研究
- DOI:
10.1016/s2352-3018(24)00276-5 - 发表时间:
2025-02-01 - 期刊:
- 影响因子:13.000
- 作者:
Steven K Grinspoon;Markella V Zanni;Virginia A Triant;Amy Kantor;Triin Umbleja;Marissa R Diggs;Sarah M Chu;Kathleen V Fitch;Judith S Currier;Gerald S Bloomfield;José L Casado;Mireia de la Peña;Lori E Fantry;Edward Gardner;Judith A Aberg;Carlos D Malvestutto;Carl J Fichtenbaum;Michael T Lu;Heather J Ribaudo;Pamela S Douglas - 通讯作者:
Pamela S Douglas
Carl J Fichtenbaum的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carl J Fichtenbaum', 18)}}的其他基金
University of Cincinnati AIDS Clinical Trials Unit- UC ACTU
辛辛那提大学艾滋病临床试验中心 - UC ACTU
- 批准号:
8391250 - 财政年份:2007
- 资助金额:
$ 166.84万 - 项目类别:
University of Cincinnati AIDS Clinical Trials Unit- UC ACTU
辛辛那提大学艾滋病临床试验中心 - UC ACTU
- 批准号:
7996032 - 财政年份:2007
- 资助金额:
$ 166.84万 - 项目类别:
University of Cincinnati AIDS Clinical Trials Unit- UC ACTU
辛辛那提大学艾滋病临床试验中心 - UC ACTU
- 批准号:
7575252 - 财政年份:2007
- 资助金额:
$ 166.84万 - 项目类别:
University of Cincinnati AIDS Clinical Trials Unit- UC ACTU
辛辛那提大学艾滋病临床试验中心 - UC ACTU
- 批准号:
7743091 - 财政年份:2007
- 资助金额:
$ 166.84万 - 项目类别:
University of Cincinnati AIDS Clinical Trials Unit- UC ACTU
辛辛那提大学艾滋病临床试验中心 - UC ACTU
- 批准号:
7340724 - 财政年份:2007
- 资助金额:
$ 166.84万 - 项目类别:
ACTG A5108 Efavirenz/Nelfinavir Study
ACTG A5108 依非韦伦/奈非那韦研究
- 批准号:
7044179 - 财政年份:2003
- 资助金额:
$ 166.84万 - 项目类别:
HIV Protease Inhibitors and Calcium Channel Blockers
HIV 蛋白酶抑制剂和钙通道阻滞剂
- 批准号:
7044193 - 财政年份:2003
- 资助金额:
$ 166.84万 - 项目类别:
EPIDEMIOLOGY AND OUTCOME OF STDS IN DRUG USERS
吸毒者性传播疾病的流行病学和结果
- 批准号:
2458444 - 财政年份:1996
- 资助金额:
$ 166.84万 - 项目类别:
EPIDEMIOLOGY AND OUTCOME OF STDS IN DRUG USERS
吸毒者性传播疾病的流行病学和结果
- 批准号:
2897970 - 财政年份:1996
- 资助金额:
$ 166.84万 - 项目类别:
EPIDEMIOLOGY AND OUTCOME OF STDS IN DRUG USERS
吸毒者性传播疾病的流行病学和结果
- 批准号:
2123236 - 财政年份:1996
- 资助金额:
$ 166.84万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 166.84万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 166.84万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 166.84万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 166.84万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 166.84万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 166.84万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 166.84万 - 项目类别: